Literature DB >> 9647547

Cost considerations with infertility therapy: outcome and cost comparison between health maintenance organization and preferred provider organization care based on physician and facility cost.

B VanderLaan1, V Karande, C Krohm, R Morris, D Pratt, N Gleicher.   

Abstract

Of 98 retrospectively selected patient couples insured under one scheme (group I) who, based on performance of a hysterosalpingogram (HSG), were assumed to be under active infertility care, 96 were confirmed as infertile. These were matched by date, patient age and time of HSG to 96 patients under infertility care (group II). Both patient populations were then prospectively evaluated for outcome and cost of treatment. Total physician charges for groups I and II were similar. However, charges per achieved clinical pregnancy were higher in group I than group II since group I patients demonstrated a lower pregnancy rate (28/96, 29%) than group II patients (41/96, 43%) (P=0.05). Within group I, pregnancy rates were identical, whether treatment was provided by generalists or subspecialists. In group II, all care was provided by specialists. The number of days of treatment did not vary between groups I and H, though generalists in group I provided significantly fewer treatment days than specialists in either group I (P=0.003) or in group II (P=0.021). This was primarily due to a significantly higher patient drop-out rate in group I patients, and especially amongst those who received care from generalists (P < 0.0019). Group I patients also encountered significantly more surgical procedures than group H patients (P=0.0016). If physician charges are discounted and customary surgical facility costs are added, the actual cost structure for fertility care in group I patients was dramatically higher than in group II patients. The most cost-effective format to provide infertility care of high quality appears to be a managed care setting in which subspecialists provide a majority of care and in which patient choice is restricted to those subspecialists.

Entities:  

Mesh:

Year:  1998        PMID: 9647547     DOI: 10.1093/humrep/13.5.1200

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  4 in total

1.  Reflections and comments on regulations of biotechnologies that touch the beginning of human life.

Authors:  Norbert Gleicher
Journal:  J Assist Reprod Genet       Date:  2005-01       Impact factor: 3.412

2.  First contact: the intersection of demographics, knowledge, and appraisal of treatment at the initial infertility visit.

Authors:  Krista J Childress; Angela K Lawson; Marissa S Ghant; Gricelda Mendoza; Eden R Cardozo; Edmond Confino; Erica E Marsh
Journal:  Fertil Steril       Date:  2015-05-21       Impact factor: 7.329

3.  Cost-effectiveness of screening strategies for Chlamydia trachomatis using cervical swabs, urine, and self-obtained vaginal swabs in a sexually transmitted disease clinic setting.

Authors:  Diane R Blake; Nancy Maldeis; Mathilda R Barnes; Andrew Hardick; Thomas C Quinn; Charlotte A Gaydos
Journal:  Sex Transm Dis       Date:  2008-07       Impact factor: 2.830

4.  Development and Evaluation of GIS-Based Chlamydia Trachomatis Intervention Policy in Illinois.

Authors:  Wiley D Jenkins
Journal:  Online J Public Health Inform       Date:  2009-12-10
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.